Clinical trials: Cognitive Change
Caffeine, Cognitive Change
Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine
This will be a (2 visit) double-blind, randomized, crossover design clinical study to assess the potential benefits of ER-CAFF versus IR-CAFF by assessing its impact on side effect profiles, mood states, alertness, and cognitive…
- Conditions
- Caffeine, Cognitive Change, Mood, Mood Change
- Trial name
- NCT06441695
- Testing
- xumXR extended release caffeine, immediate release caffeine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Obesity, Behavior, Health
Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention
The aim of this study is to compare brain changes in individuals with overweight or obesity enrolled in either the Noom Healthy Weight program or a matched control.
- Conditions
- Obesity, Behavior, Health, Weight Loss
- Trial name
- NCT04522245
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Healthy
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem…
- Trial name
- NCT01345864
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cognitive Change
Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
An open-label, multi-site, validity and reliability study to obtain data on the Cognivue 5-Minute Screening and Cognivue 10-Minute Assessment tests to assess scoring and normative ranges and compare against other cognitive tests…
- Trial name
- FOCUS (NCT05712005)
- Where
- United States
- Volunteers
- 1,437 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
Healthy Male Adults
Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Oxytocin (OT) is a small, naturally occurring peptide currently in clinical use to stimulate lactation in breastfeeding women. The intranasal administration of OT has recently attracted attention as a potential novel treatment in…
- Trial name
- NCT01983514
- Testing
- 8IU intranasal oxytocin, 24 IU intranasal oxytocin, 1 IU intravenous oxytocin
- Where
- Norway
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- OptiNose AS
Down Syndrome
Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30
To evaluate the suitability (i.e. number of tests completed and number of participants completing the tests, variance estimate of baseline and of the change from baseline values) of neurocognitive tests and functioning scales in…
- Trial name
- NCT02431117
- Where
- 7 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Chugai Pharmaceutical
Mood Disturbance, Mood Change
Mood and Cognitive Effects of Psilocybin in Healthy Participants
This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic…
- Conditions
- Mood Disturbance, Mood Change, Sleep Disturbance, Drug Effect
- Trial name
- MELO (NCT05252598)
- Testing
- Psilocybin, Inonotus Obliquus Whole Extract
- Volunteers
- healthy volunteers welcome
- Sponsor
- Optimi Health Corporation
Change in Cognitive Function and Fatigue During Extended Performance of the Cognitive Demand Battery (CDB) at 1, 3 and 6 Hours Post Consumption, Change in Long Term Declarative Memory at 1, 3 and 6 Hours Post-intervention.
Plant Based Extracts and Cognition
Acute, randomized, placebo controlled, double blind, 4 arm crossover study to determine the effect of different combinations of plant based extracts on cognitive function and cerebral blood flow.
- Trial name
- CEOPTB (NCT02202629)
- Testing
- Beverage containing plant based extracts
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Burnout, Risk Reduction
Effectiveness of Online Therapy to Prevent Burnout
This study aims to address the reliability and validity of the Empowerment for Participation (EFP) batch of assessments to measure Burnout risk in relation to the efficacy of online interventions to provide proactive…
- Conditions
- Burnout, Risk Reduction, Cognitive Change
- Trial name
- NCT05343208
- Testing
- EFP Psychometric assessment to determine level of afflication
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- SciensCollege
Healthy
A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement With Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline
The objective of this study is to evaluate the efficacy of a NeuroQ supplement designed by Dr. Bredesen to complement his Lifestyle modification protocol.
- Trial name
- NCT04149639
- Testing
- NeuroQ
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- LifeSeasons Inc.
Mucopolysaccharidosis Type II, Metabolic Diseases
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.
- Trial name
- NCT05208281
- Testing
- GNR-055 1.0-2.0-3.0 mg/kg, GNR-055 2.0 mg/kg, GNR-055 3.0 mg/kg
- Where
- 5 sites in Russia
- Volunteers
- 32 people
- Sponsor
- AO GENERIUM
Alzheimer's Disease
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
1. To evaluate the diagnostic performance of [18F]-APN-1607 injection PET imaging in detecting uptake patterns consistent with AD neuropathological changes as defined by the National Institute on Aging-Alzheimer's Association…
- Trial name
- NCT07752784
- Testing
- [18F]-APN-1607
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Cognitive Change
Improved Cognitive Outcomes Associated With Feihe HMO With DHA/ARA in Infant Formula
The goal of this interventional clinical trial is to test the effectiveness of improving cognitive development in newly born infants fed with Feihe investigational formula product containing HMO, and DHA/ARA.
- Trial name
- NCT06146387
- Testing
- Investigational Formula, Control Formula, Breastfeeding
- Where
- 3 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Heilongjiang Feihe Dairy Co. Ltd.
Healthy, Cognitive Change
Cognitive Augmentation Via Multimodal Sensing and Auricular Neurostimulation
The goal of this clinical trial is to extend this period of optimal cognitive performance by applying neurostimulation to buffer health volunteers against the effects of increased levels of stress, distraction, and cybersickness.
- Conditions
- Healthy, Cognitive Change, Effects of External Neurostimulation on Cognition
- Trial name
- CAMSAN (NCT06782360)
- Testing
- Active Neurostimulation
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- OpenBCI
Schizophrenia
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable…
- Trial name
- NCT02079844
- Testing
- Roflumilast, Second generation antipsychotic
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Takeda
Clinical High Risk for Psychosis (CHR)
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks.
- Trial name
- NCT07226895
- Testing
- MT1988 Low Dose, MT1988 High Dose
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- Monument Therapeutics Limited
Cognitive Change, Sleep Deprivation
Sleep Deprivation Study
The purpose of this study is to evaluate the measures of brain function, both neurophysiological (event-related potentials (ERPs) and functional (cognitive assessments), in response to sleep deprivation.
- Conditions
- Cognitive Change, Sleep Deprivation, Caffeine
- Trial name
- NCT05560620
- Testing
- Sleep Deprivation, Caffeine, No Caffeine
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- NeuroCatch Inc.
Stress
Acute Stress Recovery
The proposed study aims to evaluate whether different features of a relaxation room affect how individuals recover from acute stress.
- Trial name
- ASR (NCT05298189)
- Testing
- MindBreaks - Audio-visual, MindBreaks - Auditory-only, MindBreaks - Visual-only
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Well Living Lab, Inc.
Alzheimer's Disease
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
- Trial name
- NCT01703702
- Testing
- florbetapir (18F)
- Where
- 57 sites in United States, France and 1 more
- Volunteers
- 641 people
- Sponsor
- Avid Radiopharmaceuticals
Addiction;Drug(S);LSD, Neuroprotective
Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances
Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions.
- Trial name
- NCT06550167
- Testing
- Nano-PSO, Pomegranate seed oil (omega-5)
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Distribuidora Biolife SA de CV